Sign in
TG

TransMedics Group, Inc. (TMDX)·Q1 2024 Earnings Summary

Executive Summary

  • TMDX delivered a high-watermark quarter: revenue $96.9M (+133% YoY; +19% QoQ), gross margin 62% (up 300 bps QoQ), and GAAP diluted EPS $0.35; management raised FY24 revenue guidance to $390–$400M from $360–$370M .
  • Growth drivers were broad-based: higher OCS utilization across liver/heart/lung via NOP and ramping transplant logistics (logistics revenue ~$14.5M; service mix 36.7%); product margin was 77% and service margin 36% .
  • Strategic momentum: aviation/logistics scaling (14 owned aircraft; 49% of NOP missions flown on owned fleet; 105 programs using logistics), and three new clinical programs (OCS Lung prolonged perfusion; OCS Heart warm therapeutic perfusion; OCS Heart cold oxygenated perfusion for <6h) to drive adoption and expand indications .
  • Outlook: management expects modest sequential growth through 2024 and improving gross margin over the next 12–18 months; service mix seen at ~37–39% in 2024 .

What Went Well and What Went Wrong

What Went Well

  • Broad-based revenue strength: $96.9M (+133% YoY; +19% QoQ) driven by increased OCS utilization across all three organs and expanded logistics services; CFO cited U.S. revenue $91.9M with organ mix: liver $67.0M, heart $20.2M, lung $4.7M .
  • Margin improvement QoQ despite higher service mix: overall gross margin 62% (vs 59% in Q4); product margin normalized to 77%, service margin 36% as logistics scaled .
  • Scalable logistics infrastructure: 14 owned aircraft; daily active planes 9 (vs 7 in Q4); owned aircraft flew ~49% of NOP missions (vs 35% in Q4); 105 programs used logistics, supporting reliability and cost efficiency .

Quote: “We fully expect our future growth to be driven by both increased product and transplant logistics adoption.” — CEO Waleed Hassanein .

What Went Wrong

  • YoY gross margin compression: 62% vs 69% in Q1’23, reflecting a higher proportion of lower-margin service revenue (NOP clinical and logistics) .
  • Cash decreased $44.6M QoQ to $350.2M primarily due to ~$39M for three additional jets, underscoring ongoing capital needs to scale aviation (though operating profitability improved) .
  • Service margins remain structurally lower than product (36% vs 77% in Q1), so mix shift toward services can weigh on consolidated gross margin if not offset by scale efficiencies .

Financial Results

Summary P&L vs prior year and prior quarter (oldest → newest)

MetricQ1 2023Q4 2023Q1 2024
Revenue ($M)$41.6 $81.2 $96.9
Gross Margin %69% 59% 62%
Operating Expenses ($M)$30.9 $45.3 $47.5
Net Income ($M)-$2.6 $4.0 $12.2
Diluted EPS ($)-$0.08 $0.12 $0.35

Revenue mix and margins (oldest → newest)

MetricQ1 2023Q4 2023Q1 2024
Product Revenue ($M)$34.0 $51.9 $61.3
Service Revenue ($M)$7.6 $29.3 $35.5
Service % of Total18.2% 36.1% 36.7%
Product Margin %N/A73% 77%
Service Margin %N/A35% 36%

Regional and organ detail (Q1 2024 snapshot)

MetricQ1 2024
U.S. Revenue ($M)$91.9
ex-U.S. Revenue ($M)$4.1
U.S. Liver Revenue ($M)$67.0
U.S. Heart Revenue ($M)$20.2
U.S. Lung Revenue ($M)$4.7

KPIs and operating metrics

KPIQ4 2023Q1 2024
Logistics Revenue ($M)$9.2 $14.5
Owned Aircraft (count)11 at YE; avg active 7 planes in Q4 14 owned; avg active 9 planes
% NOP Missions on Owned Aircraft35% 49%
Programs Using Logistics (count)~97–98 ~105
NOP Share of Case Volume>98% >98%
Cash ($M)$394.8 $350.2

Actual vs. Consensus

  • S&P Global consensus estimates for Q1 2024 were unavailable at time of analysis due to data access limits; therefore, we cannot present vs. estimates for revenue or EPS for this quarter. We will update when S&P Global data becomes available.

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
RevenueFY 2024$360M–$370M $390M–$400M Raised
  • Qualitative color: management expects modest sequential growth through 2024 and ongoing gross margin improvement over 12–18 months; service mix expected ~37–39% in 2024 .

Earnings Call Themes & Trends

TopicPrevious Mentions (Q3’23, Q4’23)Current Period (Q1’24)Trend
Aviation/logistics scalingSummit acquisition; early logistics revenue ($2.1M in Q3), 11 planes at YE; Q4: $9.2M logistics, avg 7 active planes, 98 programs, 35% NOP flights covered 14 owned planes; avg 9 active; 49% NOP flights covered; ~105 programs; aim 15–20 planes by YE, 25–30 by end 2025; target 80%+ mission coverage over time Strong positive scale and adoption
Gross margin trajectoryGM 61% in Q3 with transition headwinds; 59% in Q4; expectation to improve through 2024 (exit 63–64%) GM 62% (+300 bps QoQ); product 77%, service 36%; confidence in further improvement over 12–18 months Improving QoQ; targeting scale benefits
OCS adoption & clinical outcomesMarket share gains and national transplant volume growth; plan to publish outcomes at conferences ISHLT presentations supporting OCS Heart/Lung outcomes; narrative that outcomes underpin adoption and growth Evidence base strengthening; supports demand
Regulatory/legal backdropAddressed congressional letter; asserted inaccuracies; no expected direct impact Focus on execution; ex-US NOP clinical support replication (reimbursement first) Legal noise fading; international optionality
R&D/Clinical programsNext-gen OCS platform; plans to reinvigorate lung Three major programs: OCS Lung prolonged perfusion; OCS Heart warm perfusion; OCS Heart cold oxygenated perfusion <6h (new indication) Pipeline advancing; indication expansion targeted
Product-service mix2024 view: ~65% product / 35% service Service mix trending 37–39% Slightly higher service mix

Management Commentary

  • “We are pleased with our first quarter results as we simultaneously drove continued revenue growth, expanded our infrastructure, and achieved profitability.” — CEO Waleed Hassanein .
  • “We fully expect our future growth to be driven by both increased product and transplant logistics adoption.” — CEO Waleed Hassanein .
  • “Gross margin for the first quarter of 2024 was 62%... up from 59% last quarter… We are extremely confident that we will be able to further improve the gross margin over the next 12 to 18 months.” — CEO Waleed Hassanein .
  • “In Q1, product revenue was $61.3 million, and service revenue was $35.5 million… Product margin was 77%… Service margin was 36%.” — CFO Stephen Gordon .
  • “We depreciate the planes over 10 years with a 50% residual value.” — CFO Stephen Gordon .

Q&A Highlights

  • Guidance cadence and seasonality: Management modeled modest sequential growth and incorporated plane maintenance downtime and summer seasonality; does not expect a down sequential quarter .
  • Mix and margins: Service share expected ~37–39% in 2024; despite higher service mix, overall GM expected to continue improving with scaling .
  • Aviation scale: Targeting 15–20 operational aircraft by YE 2024, 25–30 by end 2025 to reach ~80% coverage of NOP missions; logistics seen as cost-efficient and reliable by programs .
  • Clinical roadmap: Launching trials to increase OCS Lung perfusion duration and to expand OCS Heart indications; positioning warm perfusion versus cold options given outcome data; cold oxygenated perfusion program limited to <6h to protect outcomes .
  • International expansion: Active discussions to replicate NOP clinical support ex-U.S. (Europe, Middle East), prioritizing reimbursement; no logistics/surgical procurement ex-U.S. initially .

Estimates Context

  • S&P Global (Capital IQ) consensus estimates for Q1 2024 were unavailable due to data access limits at the time of this analysis. As a result, we cannot present quantitative “vs. estimates” comparisons for revenue/EPS this quarter. We will refresh with S&P Global data when accessible.

Key Takeaways for Investors

  • Durable growth vectors: Broad OCS adoption across organs plus a rapidly scaling logistics platform support continued double-digit growth; FY24 revenue guidance raised to $390–$400M .
  • Margin trajectory improving: Consolidated GM expanded 300 bps QoQ to 62% with product margin normalization (77%) and service efficiency gains (36%); further uplift expected with scale .
  • Logistics advantage as moat: Controlled fleet (14 planes) and dispatch network now cover ~49% of NOP flights, improving availability, safety, and cost structure—key differentiator versus brokered model .
  • Pipeline as catalyst: Three clinical programs (lung and heart) aim to expand indications and showcase outcome superiority—potentially unlocking new volume and mix opportunities .
  • Watch service mix and cap intensity: Higher service mix can weigh on GM; aviation scaling requires capital (cash down $44.6M QoQ largely due to aircraft purchases), but operating leverage appears to be improving .
  • Near-term setup: Management modeled prudent seasonality/maintenance into guidance yet still expects modest sequential growth; catalysts include clinical data flow and logistics ramp execution .